MK-1697
Biological
Merck Sharp & Dohme Corporation
Total Payments
$16,526
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1,741 | 2 | 0 |
| 2018 | $14,785 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,526 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Study of MK-1697 in Participants with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $16,526 | 0 |
Top Doctors Receiving Payments for MK-1697
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $16,526 | 4 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $16,526
Product Information
- Type Biological
- Total Payments $16,526
- Total Doctors 0
- Transactions 4
About MK-1697
MK-1697 is a biological associated with $16,526 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2019. In 2019, $1,741 was paid across 2 transactions to 0 doctors.
The most common payment nature for MK-1697 is "Unspecified" ($16,526, 100.0% of total).
MK-1697 is associated with 1 research study, including "A Phase 1 Study of MK-1697 in Participants with Advanced Solid Tumors" ($16,526).